SRNE

AcronymDefinition
SRNESport Riders of New England
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
Shares of Sorrento Therapeutics (SRNE) are rallying after Matthew Herper of Forbes reported that Celularity, a company spun out of Celgene (CELG), raised $250M with the aim of developing cells from placentas to attack tumors and to treat Crohn's disease.
Sorrento Therapeutics Inc (NASDAQ: SRNE), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, announced yesterday that it has completed its earlier announced underwritten public offering of 23,625,084 shares of its common stock at a public offering price of USD2.00 per share, before deducting underwriting discounts and commissions and estimated offering expenses payable by the company.
Wainwright analyst Raghuram Selvaraju says the acquisition of Juno Therapeutics (JUNO) by Celgene (CELG) bodes well for Sorrento Therapeutics (SRNE).
Biopharmaceutical company Sorrento Therapeutics Inc (NASDAQ: SRNE) revealed on Wednesday that its subsidiary TNK Therapeutics has launched a binding term sheet to acquire Virttu Biologics Limited.
18 November 2016 - California-based biopharmaceutical company Sorrento Therapeutics, Inc.'s (NASDAQ: SRNE) TNK Therapeutics, Inc.
(NASDAQ: SRNE) and US-based pain drug developer Scilex Pharmaceuticals Inc.
It was reported yesterday that Sorrento Therapeutics Inc (NASDAQ: SRNE), an antibody-centric, clinical stage biopharmaceutical company, has named Miranda Toledano as its new Executive Vice President of Corporate Development of Sorrento and President of LA Cell, Sorrento's Joint Venture with City of Hope.
Sorrento Therapeutics Inc (NASDAQ: SRNE), an antibody-centric, clinical stage biopharmaceutical company developing new treatments for cancer, inflammation and autoimmune diseases, announced yesterday that it has named Kevin M Herde as its executive vice president and chief financial officer.
US-based drugmaker Sorrento Therapeutics, Inc.'s (NASDAQ: SRNE) Scintilla Pharmaceuticals, Inc subsidiary has entered into a binding term sheet to acquire pain drug specialist Semnur Pharmaceuticals, Inc, the company said.
16 August 2016 - US-based drugmaker Sorrento Therapeutics, Inc.'s (NASDAQ: SRNE) Scintilla Pharmaceuticals, Inc subsidiary has entered into a binding term sheet to acquire pain drug specialist Semnur Pharmaceuticals, Inc, the company said.